Overview

• Trump announced a planned TrumpRx site for discounted direct purchases, with the White House hoping to launch in early 2026.
• CMS official Chris Klomp said Pfizer agreed not to charge the U.S. more than other countries for any drug across Medicare, Medicaid and cash sales.
• The administration says TrumpRx will convene manufacturer offers rather than run distribution, with no decision announced on insurance use.
• Officials touted listings that will often reflect full Most-Favored-Nation pricing, with some discounts described as up to 80% below current prices.
• Pfizer committed $70 billion to U.S. manufacturing and secured a three-year tariff reprieve, while PhRMA plans a separate direct-sale portal for January 2026.